Background--Macrophage-mediated chronic inflammation is mechanistically linked to insulin resistance and atherosclerosis. Although arginase I is considered antiinflammatory, the role of arginase II (Arg-II) in macrophage function remains elusive. This study characterizes the role of Arg-II in macrophage inflammatory responses and its impact on obesity-linked type II diabetes mellitus and atherosclerosis.
1 (Th1) cytokines (eg, interferon-γ ). The M1 phenotype is associated with increased production of chemoattractants, such as monocyte chemoattractant protein (MCP) 1, and of numerous proinflammatory cytokines, including interleukin (IL) 6 and tumor necrosis factor (TNF) α, and is linked to inflammatory diseases, such as obesity-associated insulin resistance and atherosclerosis. 6 In contrast, M2 macrophages are triggered by the Th2 cytokines (eg, IL4 or IL13), are characterized by the production of antiinflammatory cytokines such as IL10, and are considered to participate in resolution of the inflammatory responses. 7, 8 Evidence recently has been presented that reactive oxygen species (ROS) such as superoxide anion (O 2
•− ) and hydrogen peroxide (H 2 O 2 ), especially mitochondrial ROS, are important signals that provoke elevated production of proinflammatory cytokines in monocytes/macrophages. 12 ROS are defense mechanisms and play an essential role in immune responses to pathogens, but they also contribute to the pathophysiology of inflammatory diseases, including type II diabetes mellitus and atherosclerosis. 13, 14 Among other genes, arginase has been demonstrated to be involved in macrophage inflammatory responses through regulation of inducible nitric oxide synthase (iNOS). 15 The underlying mechanism is attributed to depletion of specific intracellular L-arginine pools for NOS by metabolizing L-arginine to L-ornithine and urea. 15 There are 2 isoenzymes of arginase, arginase I (Arg-I) and arginase II (Arg-II), which are encoded by different genes. 16 Whereas Arg-I is a cytoplasmic enzyme and primarily functions in the urea cycle involved in ammonia detoxification in the liver, Arg-II is located in mitochondria and is widely expressed in extrahepatic tissues, particularly the kidney. 16 Macrophages express both Arg-I and Arg-II. 17 Numerous studies have shown that the enhanced expression of Arg-I in M2 cells limits the bioavailability of intracellular L-arginine for excessive nitric oxide production from iNOS and dampens inflammation and tissue damage, [18] [19] [20] contributing to the antiinflammatory functions of M2 cells. 21, 22 Specific targeting of Arg-I in macrophages has been shown to suppress clearance of intracellular pathogens by decreasing nitric oxide production. 23 In contrast to Arg-I, only a few studies have attempted to elucidate the role of Arg-II in macrophage inflammatory responses. One study proposed that Arg-II plays a role in antiinflammatory responses on the basis of the association between Arg-II and liver X receptor in macrophages. 24 Another study observed that bone marrow-derived macrophages subjected to proinflammatory stimuli express Arg-II exclusively and that the accumulation of Arg-II-expressing macrophages is associated with advanced atherosclerotic lesions, which suggests a proinflammatory role of Arg-II in macrophages. 17 The results from these studies yielded completely opposite conclusions. Moreover, evidence for a functional role of Arg-II in macrophages is lacking. The effect of Arg-II gene disruption on macrophage inflammation in vivo in a chronic inflammatory disease model, such as type II diabetes mellitus and atherogenesis, has not been investigated, although treatment of apolipoprotein E-deficient (ApoE −/− ) mice with nonspecific arginase inhibitors has been shown to reduce atherosclerosis. 25 Our study is therefore focused on characterization of the functions of Arg-II in regulation of macrophage inflammatory responses and of the underlying molecular mechanisms, by means of specific genetic approaches. Moreover, the impact of the genetic targeted disruption of Arg-II on pathogenesis of chronic inflammatory diseases (ie, obesitylinked type II diabetes mellitus and atherosclerosis) also is studied.
Methods Materials
Reagents were purchased or obtained from the following sources: Normal chow (NC; energy content: 12% fat, 28% protein, and 60% carbohydrate) was purchased from UAR, Epinay sur Orge, France. A high-fat diet (HF; energy content: 55% fat, 21% protein, and 24% carbohydrate; Harlan Teklad TD 93075) and a high-cholesterol diet (HC; energy content: 42.6% fat, 15.5% protein, and 41.9% carbohydrate; 1.3% cholesterol; Harlan Teklad TD.02828) were from Harlan, Horst, the Netherlands. LPS, thioglycollate medium, Nacetylcysteine (NAC), 2 ,7 -dichlorofluorescein (H 2 DCF), propidium iodide solution, and anti-tubulin (T5168) monoclonal antibody were from Sigma (Buchs, Switzerland). Hoechst 33342 Stain was from ThermoFisher Scientific (Wohlen, Switzerland). Recombinant human TNFα was purchased from Brunschwig (Basel, Switzerland). Human oxLDL was a product of INTRACEL and was purchased from Chemie Brunschwig AG (Basel, Switzerland). Anti-Arg-I antibody (#610708) was from BD Transduction Laboratories (Allschwil, Switzerland), and anti-Arg-II antibody (sc-20151) was from Santa Cruz (Nunningen, Switzerland). Anti-F4/80 (MCA497G) and anti-CD11c (MCA1369EL) were from AbD Serotec (Düsseldorf, Germany). Rabbit anti-MMP14 (ab51074) was from Abcam (Cambridge, UK). Rabbit anti-iNOS (#06-573) was from Upstate (Luzern, Switzerland). IRDye 800-conjugated goat anti-rabbit IgG F(c) was purchased from LI-COR GmbH (Bad Homburg, Germany). CFDA-SE (carboxyfluorescein diacetate, succinimidyl ester), MitoSox, Alexa Fluor 680-conjugated anti-mouse IgG (H+L), Alexa Fluor 488-conjugated anti-hamster, and Alexa Fluor 546-conjugated anti-rat and anti-rabbit IgG were from Invitrogen (Lubioscience, Luzern, Switzerland). Alexa Fluor 647-conjugated anti-CD11b antibody was from eBioscience (Vienna, Austria).
Animals
The Arg-II-deficient mice (Arg-II −/− ) were kindly provided by Dr William O'Brien 26 and were backcrossed to C57BL/6J more than 8 generations. Genotyping was performed by polymerase chain reaction as previously described. 26 The wild-type and Arg-II −/− offspring from hetero/hetero crossing were interbred to obtain wild-type and Arg-II −/− mice, respectively, for experiments. Starting at the age of 7 weeks, the male wildtype and Arg-II −/− mice were given free access for 14 weeks to either a normal chow (NC) or a high-fat (HF) diet. A glucose tolerance test (GTT) and an insulin tolerance test (ITT) were performed after 6 hours of fasting in the twelfth and thirteenth weeks of HF diet, respectively. After 14 weeks of HF, animals were euthanized, followed by collection of blood, peritoneal macrophages, bone marrow, and tissues. The isolated tissues either were subjected to immunofluorescence staining or were snap-frozen in liquid nitrogen and kept at −80 • C until processed. The blood samples were collected after 6-hour starvation.
The ApoE −/− mice (Jackson Laboratory, Bar Harbor, Maine) and Arg-II −/− mice, both on a C57BL/6J background, were interbred to obtain ApoE −/− Arg-II −/− mice. To accelerate atherosclerotic lesion formation, 10-week-old male ApoE −/− Arg-II +/+ and ApoE −/− Arg-II −/− mice were fed either the HF diet or a high-cholesterol (HC) diet for 10 weeks. At 20 weeks of age, animals were anesthetized with ketamine (100 mg/kg IP) and xylazine (10 mg/kg IP), and the entire aorta from the heart to the iliac bifurcation was removed and dissected free from fat and adhering perivascular tissue. The aortic roots were snap-frozen in Optimal Cutting Temperature compound. The 7-μm-thick cryosections of the aortic roots and the entire thoracic-abdominal aortas were stained with Oil Red O to assess lesion size, and the size of the necrotic core was evaluated by hematoxylin-eosine staining of paraffinembedded sections of the aortic arches. The sizes of the lesion and the necrotic core were quantified with the ImageJ software (US National Institutes of Health). At least 7 equally spaced aortic root cryosections or 4 equally spaced arch-paraffin sections per mouse were evaluated. The blood samples were collected after overnight starvation. Housing and animal experimentation were approved by the Swiss Federal Veterinary Office.
Generation of Recombinant Adenoviruses
Expressing Murine Arg-II and Short Hairpin RNA Generation of recombinant adenovirus (rAd) expressing murine Arg-II driven by cytomegalovirus (CMV) promoter (rAd/CMVArg-II) and short hairpin RNA (shRNA) targeting human Arg-II (hArg-II) driven by the U6 promoter (rAd/U6-hArg-II shRNA ) was carried out with the Gateway technology (Invitrogen Life Technologies) according to the manufacturer's instructions. rAd/CMV-bacterial β-galactosidase (LacZ) and rAd/U6-LacZ shRNA were used as controls for rAd/CMV-Arg-II and rAd/U6-hArg-II shRNA , respectively. The pCMV6 construct encoding the murine Arg-II was obtained from Origene. The human Arg-II targeting sequence for rAd/U6-hArg-II shRNA is indicated in boldface below (only the sense strand is shown):
CACCGCGAGTGCATTCCATCCTGAACGAATTCAGGATGGAATG CACTCGC
Cell Culture and Adenoviral Transduction of THP-1 Cells and Bone Marrow-Derived Macrophages
Human umbilical vein endothelial cells were isolated from umbilical cords and cultivated as described. 27 The human monocytic cell line THP-1 (American Type Culture Collection) was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (HIFBS).
Bone marrow-derived macrophages were prepared from bone marrow-derived cells by incubation with 10% HIFBS-RPMI, supplemented with 20% of L929-conditioned medium containing macrophage colony-stimulating factor, for 6 to 7 days to induce differentiation. Treatments were carried out after 6 hours of starvation in 0.2% bovine serum albumin (BSA)-RPMI.
For adenoviral transduction of THP-1 cells, 1×10 6 THP-1 cells were harvested in 100 μL RPMI without HIFBS, and 400 μL virus was added. After incubation at 37
• C for 2 hours with rotation, 2 mL 10% HIFBS-RPMI was added. At day 4 after transduction, the transduced cells were serum-starved in 0.2% BSA-RPMI for 6 hours before the experiments. For adenoviral transduction of bone marrow-derived macrophages, bone marrow-derived macrophages at day 6 or 7 after differentiation were transduced with rAd at a multiplicity of infection of 100 and were further incubated in 10% HIFBS-RPMI without L929-conditioned medium for 2 days. Cells were starved in 0.2% BSA-RPMI for 6 hours, and then they were either treated with 0.1 μg/mL LPS or left untreated for 22 hours. 
Immunoblotting Analysis

Peritoneal Macrophage Harvest
Peritoneal macrophages were obtained and purified as described previously. 28 Peritoneal macrophages were harvested with or without thioglycollate elicitation (2 mL of 4% aged thioglycollate medium per mouse, 3 to 4 days) for adhesion assay or immunoblotting analysis, respectively. The macrophages then were purified by magnetic cell sorting with CD11b microbeads and LS columns, according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany).
Monocyte and Macrophage Adhesion Assay
The labeling of monocytes/macrophages and the adhesion assay were performed as described previously. 28 Briefly, the cultured THP-1 monocytes or purified peritoneal macrophages were labeled with 5 μmol/L of CFDA-SE in phosphate-buffered saline (PBS) at 37
• C for 8 minutes. The labeling was stopped with 1 mL heat-inactivated (56 • C×30 minutes) fetal calf serum for 1 minute. The labeled macrophages (2×10 5 THP-1 or 1×10 5 thioglycollate-elicited murine peritoneal macrophages) were then added to the activated human umbilical vein endothelial cells that had been treated with 10 ng/mL TNFα overnight in 12-well plates. After incubation for 15 minutes at 37
• C, the cells were washed twice with PBS, and images of adherent monocytes or macrophages were captured under the fluorescent microscope (5 different fields per sample). The number of adherent monocytes or macrophages was counted with the ImageJ software (US National Institutes of Health) by a researcher who was blinded to the experimental protocols.
Adoptive Transfer
Twenty-week-old ApoE −/− Arg-II +/+ and ApoE −/− Arg-II −/− mice that had received HC diet during the previous 10 weeks were used for adoptive transfer experiments. Monocytes were purified from the splenocytes of the donor mice by magnetic cell sorting with CD11b microbeads and LS columns, according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Preparation of splenocytes was performed as described previously. 29 The purity of monocytes was verified by flow cytometry analysis after 1×10 6 cells were incubated with Alexa Fluor 647-conjugated antiCD11b antibody. The purified monocytes were labeled with cell-permeable Hoechst 33342 Stain (4 μg/mL, 30 minutes) in 10% HIFBS-RPMI (1×10 6 cells/mL). After being washed 3 times, the labeled monocytes were resuspended at 2×10 6 /mL in 2% HIFBS-PBS. Labeled monocytes (1×10 6 ) in 500 μL of 2% HIFBS-PBS were adoptively transferred by intravenous injection into the tail veins of the recipient mice. Sixty hours after transfer, animals were anesthetized with ketamine (100 mg/kg IP) and xylazine (10 mg/kg IP) and euthanized. The aortic roots were prepared and snap-frozen in Optimal Cutting Temperature compound. The 7-μm-thick cryosections of the aortic roots were fixed with ice-cold methanol for 20 minutes, followed by counterstaining with propidium iodide solution (5 μg/mL, 5 minutes). The number of adoptively transferred labeled monocytes in atherosclerotic plaques was visualized and counted under LEICA's DMI6000 Confocal microscope. Ten equally spaced aortic root cryosections per mouse were evaluated.
Tissue Immunofluorescence Staining and Confocal Microscopy
After deparaffinization in xylene, hydration in ethanol, and antigen retrieval in citrate buffer (10 mmol/L, pH 6.5) in a microwave oven, paraffin-embedded sections (7 μm) were blocked with 2% BSA in PBS for 30 minutes and then were incubated with the first antibodies and subsequently with fluorescence-labeled secondary antibodies at room temperature, for 2 hours and 1 hour, respectively, followed by counterstaining with 300 nmol/L DAPI (4'6-diamidino-2-phenyl-indole, dihydrochloride, Invitrogen) for 2 minutes. The immunofluorescence signals were visualized under LEICA's DIM6000 Confocal microscope. The same procedure was applied for immunofluorescence staining of the 7-μm cryosections of aortic roots, except that the sections were fixed with either 0.4% paraformaldehyde (for anti-F4/80) or methanol (for antiCD11c and anti-MMP14).
Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction Analysis
Total RNA extraction and mRNA expression analysis by 2-step real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were performed as described previously. 30 The mRNA expression levels of all genes were normalized to the reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primer sequences are summarized in Table 1 . 
Enzyme-Linked Immunosorbent Assay
The protein level of proinflammatory mediators in the conditioned medium of RPMI containing 0.2% BSA was evaluated by enzyme-linked immunosorbent assay with the use of the ELISA MAX Deluxe from BioLegend, according to the manufacturer's instructions (Lucerna Chem AG, Luzern, Switzerland). 
Detection of Mitochondrial
GTT and ITT
GTT and ITT were performed on mice that had been fasted for 6 hours. For GTT, animals were injected intraperitoneally with glucose (1 g/kg), whereas for ITT, 0.5 U/kg human insulin (Actrapid HM, Novo-Nordisk) was injected intraperitoneally. Blood glucose was measured at 0, 15, 30, 45, 60, 90, and 120 minutes after intraperitoneal injection by a One-Touch Glucose Monitoring System Ascensia Contour (Bayer). 
Measurement of Blood Parameters
Results
Arg-II Plays a Proinflammatory Role in Macrophages
In accordance with previous reports, 31 we show here that the murine macrophage cell line RAW264.7, when stimulated with LPS (0.1 μg/mL) to induce M1 phenotype activation, revealed an enhanced expression of iNOS and Arg-II but not Arg-I (Figure 1A) . Similarly, stimulation of the human monocyte cell line THP-1 with LPS (0.1 μg/mL, 22 hours) upregulated Arg-II but not Arg-I ( Figure 1B) . In contrast to the RAW264.7 cells, no increase in iNOS level was observed in THP-1 cells (Figure 1B) . Moreover, differentiation of THP-1 monocytes into macrophages by the phorbol ester PMA (phorbol 12-myristate 13-acetate; 0.2 μmol/L for 3 days) also was accompanied by increased Arg-II expression without detectable upregulation of iNOS or Arg-I ( Figure 1C ). These results demonstrate that M1 activation and monocyte differentiation to macrophages are accompanied by Arg-II but not Arg-I gene upregulation.
To determine whether Arg-II is involved in proinflammatory functions of macrophages, THP-1 cells were transduced with rAd carrying shRNA against human Arg-II (rAd/U6-Arg-II shRNA ), and cell adhesion activity was assayed. Silencing of Arg-II, confirmed by immunoblotting (Figure 2A To further investigate the role of Arg-II in proinflammatory responses of macrophages, we examined the effect of silencing Arg-II on the production of proinflammatory mediators in response to proinflammatory stimuli. In THP-1 cells, both oxLDL (50 μg/mL, 24 hours) and LPS (0.1 μg/mL, 8 hours) upregulated mRNA expression of TNFα, MCP1, and IL6 in parallel with upregulation of Arg-II ( Figure 2B ). Silencing Arg-II significantly blunted the upregulation by oxLDL or LPS at both the mRNA ( Figure 2B ) and protein ( Figure 2C ) levels, demonstrating an important role of Arg-II in proinflammatory responses in monocytes/macrophages. Because the mRNA level reflects the protein level of the inflammatory mediators, the proinflammatory responses therefore were assessed by monitoring mRNA levels for further studies.
To reinforce the aforementioned findings, bone marrow cells were isolated from both wild-type and Arg-II −/− mice 26 and were differentiated ex vivo into macrophages. Gene expression of numerous proinflammatory mediators, including MCP1, TNFα, IL6, matrix metalloproteinase (MMP) 14, and iNOS, in response to LPS was reduced significantly in macrophages from Arg-II −/− mice compared to the cells from wild-type mice, as assessed by real-time qRT-PCR (Figure 3A) . The presence and absence of Arg-II gene expression validate the genotype of the mice ( Figure 3A , last graph). Of note, LPS-induced MMP14 expression was lower in Arg-II −/− macrophages than in wild-type macrophages, although the difference was not statistically significant. In agreement with the results from the cell lines shown in Figure 1A through 1C, no upregulation of Arg-I expression was detected by qRT-PCR in the macrophages upon LPS stimulation ( Figure 3B ). Most importantly, reintroduction of mouse Arg-II cDNA into the macrophages from Arg-II −/− mice not only restored but also enhanced the LPS-induced gene expression of all the previously examined proinflammatory mediators, including MMP14, to a much higher level than in the cells from wild-type mice ( Figure 3C ). The ectopic expression of Arg-II was revealed by its mRNA level in the transduced cells ( Figure 3C, last graph) . These results provide firm evidence for a proinflammatory role of Arg-II in macrophages.
To evaluate the possible role of iNOS in LPS-induced proinflammatory responses, macrophages from wild-type mice were treated with L-N G -nitroarginine methyl ester (L-NAME; Experiments were performed on day 7 after differentiation ex vivo. Cells were serum-starved for 4 h before addition of L-NAME (pretreatment for 2 h), followed by addition of LPS. Data shown are mean±SEM from 10 individual animals. *P<0.05, **P<0.01, and ***P<0.001 vs control or between indicated groups. 5 mmol/L), which inhibits all the isoforms of NOS, including iNOS, in macrophages. As shown in Figure 4 , inhibition of iNOS did not significantly affect LPS-induced upregulation of the proinflammatory mediators, including MCP1, TNFα, MMP14, and iNOS itself, except for IL6, which was, however, significantly enhanced by L-NAME. The results suggest that iNOS does not play a major role in upregulation of the proinflammatory gene expression in macrophages. Rather, it exerts certain antiinflammatory effects in the cells with regard to IL6 expression.
Arg-II Promotes Macrophage Proinflammatory Responses Through Mitochondrial ROS
To evaluate the potential mechanism by which Arg-II promotes macrophage proinflammatory responses, we then examined the effect of Arg-II on mitochondrial ROS generation. As shown in Figure 5A hours) ( Figure 5B) prevented Arg-II-mediated cytokine production, with no significant effects on the ectopic Arg-II expression ( Figure 5C ). These results demonstrate that Arg-II promotes proinflammatory cytokine production in macrophages through mitochondrial ROS.
Targeted Disruption of Arg-II Suppresses Systemic Inflammation in Type II Diabetes Mellitus
To further confirm the role of Arg-II in macrophage inflammatory responses in vivo, we took advantage of Arg-II −/− mice. Whole-body inflammation was induced by HF feeding for 14 weeks, resulting in the low-grade inflammation model of obesity-linked insulin resistance. 32 Immunoblotting analysis showed significantly increased Arg-II protein levels in peritoneal macrophages of wild-type mice fed the HF diet as compared to the levels of wild-type mice fed the NC diet ( Figure 6A ). Adhesion assays were performed with peritoneal macrophages isolated from wild-type and Arg-II −/− mice fed either the NC or the HF diet. As shown in Figure 6B , macrophages from obese wild-type mice exhibited significantly increased adhesion activity as compared to those from lean animals, whereas the increase in macrophage adhesion activity upon HF was prevented in Arg-II −/− mice, which confirms the proinflammatory role of Arg-II observed in cultured human monocytes shown in Figure 2A . We then investigated whether the HF-induced chronic inflammation in vivo can be inhibited by Arg-II gene deficiency. Indeed, the obesity-associated macrophage infiltration in wildtype animals on the HF diet, as assessed by confocal microscopic immunofluorescence staining of the pan-macrophage marker F4/80 and the proinflammatory macrophage marker CD11c, was suppressed in virtually all of the examined organs, including epididymal fat ( Figure 6C ), soleus muscle, liver, pancreas, heart, and kidney in the Arg-II −/− mice ( Figure 7 ). The macrophage infiltration in the fat tissue was characterized by typical "crown-like" structures ( Figure 6C and 6D) . Moreover, mRNA levels of the macrophage marker F4/80, CD11c, and the inflammatory mediators MCP1 and IL6 in epididymal fat as assessed by qRT-PCR were increased by HF feeding in wildtype mice; the increase was prevented or markedly blunted in Arg-II −/− mice fed the HF diet ( Figure 6E ). Although TNFα expression tended to be higher in obese wild-type than in lean wild-type mice and lower in obese Arg-II −/− than in obese wildtype mice, the difference did not reach statistical significance ( Figure 6E ). These data demonstrate a proinflammatory role of Arg-II in type II diabetes mellitus in vivo.
Targeted Disruption of Arg-II Protects HF-Induced Insulin Resistance
We further investigated whether suppressed chronic inflammation in Arg-II −/− mice protects against obesity, glucose intolerance, and insulin resistance. There was no significant difference in body weight development between wild-type and Arg-II −/− mice fed the HF diet for 14 weeks ( Figure 8A ). HF feeding increased plasma levels of cholesterol, triglyceride, and insulin to a similar extent in wild-type and Arg-II −/− mice ( Figure 9 ). As expected, HF feeding caused hyperglycemia, glucose intolerance, and impaired insulin sensitivity in wild-type mice, as assessed by GTT and ITT. Glucose tolerance and insulin sensitivity were improved significantly in Arg-II −/− mice fed the HF diet as compared to wild-type animals on the HF diet, although they were not completely normalized ( Figure 8B  and 8C ). These results demonstrate that disruption of Arg-II protects against type II diabetes mellitus independently of obesity.
Targeted Disruption of Arg-II Reduces Atherosclerosis
Next, we examined whether the decreased inflammation by Arg-II gene disruption affects another important chronic inflammatory disease: atherosclerosis. 4, 33 For this purpose, we interbred Arg-II −/− mice with atherosclerosis-prone ApoE Figure 10B) . Furthermore, the atherogenic HC diet induced more pronounced lesions through the whole aortas than did the HF diet. The surface lesion size in aortas was significantly smaller in ApoE −/− Arg-II −/− mice than in ApoE −/− Arg-II +/+ controls ( Figure 10C ). In addition, the size of necrotic No significant difference in plasma cholesterol or triglycerides was observed between the 2 groups ( Table 2 ). These results demonstrate that targeting Arg-II inhibits atherogenesis and confers features of stable plaques independently of lipid profile. Finally, we determined whether circulating monocytes contribute to the reduced macrophage inflammation in the plaque of ApoE −/− Arg-II −/− mice. For this purpose, in vivo adoptive transfer experiments were carried out. In agreement with our in vitro adhesion assay shown in Figure 2A , when ApoE −/− Arg-II −/− double-knockout (dk) donor monocytes were injected, the number of adoptively transferred monocytes found in the atherosclerotic plaques of ApoE −/− Arg-II +/+ single-knockout (sk) recipient mice was lower, as compared to the control condition in which sk donor monocytes were injected into the same genotypic recipient mice ( Figure 10F , dk→sk versus sk→sk). Conversely, recipient dk mice, when compared to recipient sk mice, accumulate fewer donor monocytes of either genotypic mice. (Figure 10F , sk→dk versus sk→sk, and dk→dk versus dk→sk). Of note, no additive reducing effect was observed when both donor monocytes and the recipient mice are deficient in Arg-II ( Figure 10F , dk→dk versus sk→dk). The results demonstrate that both circulating monocytes and the vascular microenvironment in ApoE −/− Arg-II −/− mice contribute to the reduced macrophage inflammation in atherosclerotic lesions in these animals.
Discussion
In the present study, we provide firm in vitro and in vivo evidence showing that Arg-II plays a critical role in proinflammatory responses of macrophages. Genetic targeted disruption of Arg-II in mice suppresses the inflammatory responses, thereby protecting against type II diabetes mellitus, insulin resistance, and atherosclerosis. The most important novel finding of our present study is the functional characterization of the proinflammatory role of Arg-II in macrophages. It is widely assumed that Arg-II shares its function with Arg-I in macrophages, exerting an antiinflammatory role. However, no experimental evidence has been presented so far, and results obtained from very limited studies on Arg-II in macrophages are contradictory. A previous study proposed that Arg-II plays an antiinflammatory role in macrophages, 24 yet the assumption is based solely on results showing that Arg-II gene is a direct target of liver X receptor, which has been shown to exert inhibitory effects on expression of inflammatory genes in macrophages. Another recently published study, however, demonstrated that Arg-II-expressing macrophages correlate with M1 phenotype and are associated with more advanced atherosclerosis. 17 The results from the later study suggest that Arg-II could play a proinflammatory role in macrophages. The opposing conclusions of these 2 reports with regard to the role of Arg-II in macrophage function are based on the correlations. We therefore investigated here the causative effects of Arg-II on inflammatory responses of macrophages. We went a step further by using in vitro and in vivo genetic approaches and provided compelling evidence that Arg-II promotes inflammatory responses in macrophages: (1) M1 activation of macrophages by LPS or differentiation of monocytes into macrophages is accompanied by the upregulation of Arg-II without having an effect on Arg-I expression in the cells, which is in agreement with reports from the literature. 31 Moreover, enhanced Arg-II expression also is observed in peritoneal macrophages from wild-type mice fed the HF diet as compared to those of wild-type mice fed NC, demonstrating a positive association of Arg-II with proinflammatory responses in macrophages in this chronic inflammation animal model of type II diabetes mellitus. (2) Silencing the Arg-II gene in human monocyte/macrophage cell lines decreases cell adhesion to endothelial cells and the production of proinflammatory mediators in response to oxLDL or LPS at both the mRNA and protein levels. (3) The adhesion activities of macrophages from HF-fed Arg-II −/− mice to endothelial cells also are decreased significantly compared to those from obese wild-type control mice. It is noticeable that no difference in cell adhesion is observed under NC conditions between wild-type and Arg-II −/− mice, which does not seem in line with the observations in the human monocytic cell line (Figure 2A ). This might be due to either the species difference 36, 37 or the functional differences between monocytes and macrophages. 38 The function of arginase is considered to be closely related to its involvement in the regulation of nitric oxide production through competition with iNOS for their common substrate L-arginine, which results in decreased nitric oxide production in macrophages. 39 iNOS has been considered to play a proinflammatory role in M1 macrophages upon LPS stimulation. Our results, however, do not support a major role of iNOS in mediating proinflammatory responses in macrophages with regard to proinflammatory gene expression. If Arg-II regulated inflammatory responses through iNOS, inhibition of iNOS with L-NAME would have a substantial impact on Arg-II-mediated proinflammatory cytokine gene expression. This is not the case, however. We do not observe significant effects of L-NAME on the expression of the majority of the proinflammatory genes in macrophages, except IL6, which is significantly enhanced by inhibition of iNOS with L-NAME. This result is consistent with a previous report 31 and suggests a negative regulatory role of iNOS on IL6 expression. Moreover, iNOS is not induced by LPS in the human macrophage cell line THP-1, yet Arg-II silencing in these cells still inhibits macrophage adhesion activity and expression of the proinflammatory genes. The difference in iNOS expression between human and murine macrophages is in agreement with several other studies. 36, 37 The dissociation of arginase activity from iNOS has been reported by several studies, showing that alteration of arginase activity in macrophages is not necessarily associated with functional changes in iNOS. [40] [41] [42] [43] Evidence has been presented that ROS, especially the mitochondrial ROS, promote production of proinflammatory cytokines. [9] [10] [11] In an attempt to evaluate the molecular mechanisms of Arg-II-mediated, iNOS-independent proinflammatory responses in macrophages, we demonstrated that the enhanced mitochondrial ROS are responsible for Arg-II-mediated proinflammatory responses in macrophages. This conclusion is supported by the following evidence: First, in Arg-II inflammatory responses. Given that Arg-II is a mitochondrial enzyme, 44 a pressing goal for the future will be to investigate how Arg-II affects mitochondrial function leading to mitochondrial ROS production.
Chronic macrophage inflammation is an important pathogenic mechanism shared by obesity-linked insulin resistance and atherosclerosis. In support of these notions, we show in the present study that targeted disruption of Arg-II suppresses macrophage inflammation, contributing to protection against disease development in animal models. In the obesity-linked insulin resistance model, targeted disruption of Arg-II in mice improves glucose homeostasis and protects against hyperglycemia in obese mice fed HF diet. It is of note that disruption of Arg-II does not affect plasma concentration of cholesterol, triglycerides, or insulin, nor does it affect body weight gain, which suggests that Arg-II ablation protects against type II diabetes mellitus independently of the plasma parameters and obesity, which can be attributed to decreased chronic systemic inflammation in insulin-responsive tissues. This is in agreement with a previous study reporting that ablation of the proinflammatory macrophages normalizes insulin sensitivity in obese insulin-resistant animals without affecting body weight gain. 2 In the atherosclerosis model, genetic ablation of Arg-II reduces atherosclerotic plaque formation and confers features of stable plaques: reduced lesion size, decreased necrotic core, macrophage accumulation, and proinflammatory mediators in the plaque. The results of genetic ablation of Arg-II on atherosclerosis development in our present study are in agreement with a recent report by Ryoo et al. 25 It is important to point out that in their study, a pharmacological approach was taken to assess the effect of an arginase inhibitor on atherosclerosis development in ApoE −/− mice, whereas Arg-II −/− mice were used to evaluate the role of Arg-II in atherogenic dietinduced endothelial dysfunction. In our study, we have investigated for the first time the role of Arg-II in atherosclerosis with a genetic approach, by generating ApoE −/− Arg-II −/− double-knockout mice. Moreover, we demonstrated that targeting Arg-II, in addition to preserving endothelial function, also suppresses macrophage inflammation and contributes to reduced atherosclerosis in ApoE −/− mice. Our study thus adds a novel perspective to the linkage between Arg-II and atherosclerosis. In summary, our study demonstrates that Arg-II plays a critical role in macrophage proinflammatory responses through mitochondrial ROS production, contributing to the development of both type II diabetes mellitus and atherosclerosis. Given that general inhibitors of arginase cause deleterious hyperammonemia due to inhibition of hepatic Arg-I and that no specific inhibitors of extrahepatic Arg-II are available, our study could open a new therapeutic avenue for developing specific medications targeting Arg-II for treatment of chronic inflammatory diseases, including type II diabetes mellitus and atherosclerosis. 
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